Editas Medicine to present data from RUBY, EdiTHAL trials of EDIT-301

Editas Medicine announced that a scientific abstract detailing safety and efficacy clinical data from the RUBY trial of EDIT-301 in patients with severe sickle cell disease and from the EdiTHAL trial of EDIT-301 in patients with transfusion-dependent beta thalassemia has been accepted for a poster presentation at the 65th American Society of Hematology, ASH, Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, CA, and online. Key data from patients treated in the RUBY trial and in the EdiTHAL trial will be shared, including: RUBY: Clinical data on 11 patients, including two patients with at least 12 months follow-up and an additional four patients with at least five months follow-up. Efficacy data, including total hemoglobin, fetal hemoglobin, and vaso-occlusive events, or VOEs. Safety data, including neutrophil and platelet engraftment. EdiTHAL: Clinical data on six patients, including at least five months data from the first two patients treated. Efficacy data, including total hemoglobin and fetal hemoglobin. Safety data, including neutrophil and platelet engraftment.